Milestone Pharmaceuticals Dirección
Dirección controles de criterios 3/4
El CEO de Milestone Pharmaceuticals es Joe Oliveto , nombrado en Mar 2017, tiene una permanencia de 7.67 años. compensación anual total es $1.98M, compuesta por 30.4% salario y 69.6% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.43% de las acciones de la empresa, por valor de $524.72K. La antigüedad media del equipo directivo y de la junta directiva es de 4.4 años y 5.6 años, respectivamente.
Información clave
Joe Oliveto
Chief Executive Officer (CEO)
US$2.0m
Compensación total
| Porcentaje del salario del CEO | 30.4% |
| Permanencia del CEO | 7.7yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 4.4yrs |
| Promedio de permanencia en la Junta Directiva | 5.6yrs |
Actualizaciones recientes de la dirección
Recent updates
Does Milestone Pharmaceuticals (NASDAQ:MIST) Have A Healthy Balance Sheet?
Nov 06
Here's Why Shareholders Should Examine Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) CEO Compensation Package More Closely
Jun 07Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?
Sep 13We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Mar 07We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate
Oct 15We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth
Jun 24We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely
Feb 25We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow
Aug 25Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth
Apr 02What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition
Jan 15First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT
Nov 18Milestone Pharmaceuticals EPS beats by $0.09
Nov 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$43m |
| Jun 30 2024 | n/a | n/a | -US$48m |
| Mar 31 2024 | n/a | n/a | -US$55m |
| Dec 31 2023 | US$2m | US$602k | -US$60m |
| Sep 30 2023 | n/a | n/a | -US$59m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$59m |
| Dec 31 2022 | US$3m | US$584k | -US$58m |
| Sep 30 2022 | n/a | n/a | -US$62m |
| Jun 30 2022 | n/a | n/a | -US$62m |
| Mar 31 2022 | n/a | n/a | -US$44m |
| Dec 31 2021 | US$4m | US$509k | -US$43m |
| Sep 30 2021 | n/a | n/a | -US$35m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$46m |
| Dec 31 2020 | US$4m | US$470k | -US$50m |
| Sep 30 2020 | n/a | n/a | -US$60m |
| Jun 30 2020 | n/a | n/a | -US$60m |
| Mar 31 2020 | n/a | n/a | -US$61m |
| Dec 31 2019 | US$785k | US$458k | -US$55m |
| Sep 30 2019 | n/a | n/a | -US$47m |
| Jun 30 2019 | n/a | n/a | -US$40m |
| Mar 31 2019 | n/a | n/a | -US$29m |
| Dec 31 2018 | US$1m | US$360k | -US$23m |
| Dec 31 2017 | US$851k | US$364k | -US$8m |
Compensación vs. Mercado: La compensación total de Joe($USD1.98M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD649.07K).
Compensación vs. Ingresos: La compensación de Joe ha sido consistente con los resultados de la empresa en el último año.
CEO
Joe Oliveto (56 yo)
7.7yrs
Permanencia
US$1,978,092
Compensación
Mr. Joseph G. Oliveto, also known as Joe, M.B.A. has been Chief Executive Officer and President of Milestone Pharmaceuticals Inc. March 2017 and has been its Director since July 2017. Mr. Oliveto served as...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 7.7yrs | US$1.98m | 0.43% $ 524.7k | |
| CFO & Executive VP of Corporate Development | 5.2yrs | US$1.01m | 0.029% $ 35.3k | |
| Chief Medical Officer | 2.8yrs | US$1.22m | 0.023% $ 27.8k | |
| Founder | no data | sin datos | sin datos | |
| Chief Operating Officer | 4.4yrs | sin datos | sin datos | |
| Vice President of Communications | 1.2yrs | sin datos | sin datos | |
| Vice President of Marketing | no data | sin datos | sin datos | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | 4.8yrs | sin datos | sin datos | |
| SVP of Regulatory Affairs and Quality Management | no data | sin datos | sin datos | |
| Chief Commercial Officer | 7.1yrs | US$645.72k | 0.20% $ 245.4k | |
| VP & Head of Medical Affairs | 2.3yrs | sin datos | sin datos |
4.4yrs
Permanencia media
60yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de MIST se considera experimentado (4.4 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 7.3yrs | US$1.98m | 0.43% $ 524.7k | |
| Founder | 4.8yrs | sin datos | sin datos | |
| Chief Medical Advisor & Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Observer | 7.3yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Non-Executive Director | 5.6yrs | US$153.27k | 0.023% $ 27.6k | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Chairman of the Board | 4.1yrs | US$176.77k | 0.023% $ 27.6k |
5.6yrs
Permanencia media
68yo
Promedio de edad
Junta con experiencia: La junta directiva de MIST se considera experimentada (5.6 años de antigüedad promedio).